Scioto Biosciencesincis A Clinical Stage Biotechnology Company Based In Indianapolisindianafounded In 2017 Through A Partnership Between Monon Bioventures And The Research Institute At Nationwide Childrenae S Hospitalthe Company Focuses On Developing Microbiome Based Therapeutics For Gastrointestinal Disorders And Conditions Related To The Gut Brain Axis Scioto Specializes In Its Activated Bacterial Therapeuticabtplatform Technologywhich Enhances Beneficial Bacterial Colonization In The Gutthis Approach Aims To Treat Diseases Associated With The Gastrointestinal Tract And Central Nervous Systemtheir Lead Candidatesb 121Targets Autism Spectrum Disorderasdand Related Gastrointestinal Symptomswith Ongoing Clinical Trials Showing Positive Resultsadditionallythey Have A Therapeutic Program Addressing Necrotizing Enterocolitisnecin Premature Infants The Company Has Secured Significant Fundingincluding Over $2 5 Million In Nih Grants And A $26 5 Million Series B Investment In 2023Scioto Is Dedicated To Improving The Quality Of Life For Pediatric And Adult Patients With Unmet Medical Needs Through Innovative Microbiome Therapies
United States
